Pyxis Oncology Q1 net loss widens on higher clinical trial costs

Pyxis Oncology

14/05/2026 12:11

Overview

U.S. cancer therapeutics developer's Q1 net loss widened from prior year

Operating expenses rose due to increased clinical trial costs for lead candidate MICVO

Company expects cash runway to extend into Q4 2026

Outlook

Company expects cash runway into the fourth quarter of 2026

Result Drivers

CLINICAL TRIAL COSTS - Increased research and development expenses were mainly due to higher clinical trial-related costs for MICVO monotherapy and combination therapy studies

LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to lower employee-related costs including stock-based compensation

Company press release: ID:nGNX7Hzp8W

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$23.27 mln
Q1 Basic EPS
-$0.37


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.00, about 167.2% above its May 13 closing price of $2.62

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)